India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter
03/08/2026 06:47
BUZZ-India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter ** Shares of India's Glenmark Pharmaceuticals GLEN.NS fall as much as 3.22% to 2,162 rupees
** On Friday, GLEN posted 53.6% y-o-y jump in adjusted Q1 profit, led by strong demand for its drugs that treat long-term illnesses, while revenue rose 23.1% y/y
** Company's Q1 revenue, EBITDA and adjusted profit missed estimates despite healthy year-on-year growth, Motilal Oswal says
** Brokerage says the company's Q1 sales of 40.2 billion rupees were below its estimate of 40.9 billion rupees
** GLEN rated "buy" on average by 9 analysts, median PT 2,575 rupees - data compiled by LSEG
** YTD stock up 9.44%
(Reporting by Surbhi Misra in Bengaluru)
((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter